Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy
Guardado en:
Autores principales: | Briony Adams, Alec Beaney |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/80209970dfdd4a6abe1e1bd1d4d8e4f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
por: Kohama H, et al.
Publicado: (2017) -
Disease Severity Determines Timing of Initiating Continuous Renal Replacement Therapies: A Systematic Review and Meta-Analysis
por: Zi-Jing Xia, et al.
Publicado: (2021) -
Severe postoperative hyperbilirubinemia in congenital heart disease
por: Chen Xiaolan, et al.
Publicado: (2021) -
Impact of Cumulative Fluid Balance During Continuous Renal Replacement Therapy on Mortality in Patients With Septic Acute Kidney Injury: A Retrospective Cohort Study
por: Jin Lin, et al.
Publicado: (2021) -
Increased concentrations of procalcitonin in patients with paracetamol intoxication
por: García de Guadiana Romualdo Luis, et al.
Publicado: (2021)